[go: up one dir, main page]

ZA200107978B - Low-molecular inhibitors of complement proteases. - Google Patents

Low-molecular inhibitors of complement proteases.

Info

Publication number
ZA200107978B
ZA200107978B ZA200107978A ZA200107978A ZA200107978B ZA 200107978 B ZA200107978 B ZA 200107978B ZA 200107978 A ZA200107978 A ZA 200107978A ZA 200107978 A ZA200107978 A ZA 200107978A ZA 200107978 B ZA200107978 B ZA 200107978B
Authority
ZA
South Africa
Prior art keywords
low
molecular inhibitors
complement proteases
complement
inhibitors
Prior art date
Application number
ZA200107978A
Other languages
English (en)
Inventor
Heinz Hillen
Martin Schmidt
Helmut Mack
Werner Seitz
Andreas Haupt
Johann-Christian Zechel
Andreas Kling
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag filed Critical Basf Ag
Publication of ZA200107978B publication Critical patent/ZA200107978B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B43/00—Formation or introduction of functional groups containing nitrogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
ZA200107978A 1999-04-09 2001-09-28 Low-molecular inhibitors of complement proteases. ZA200107978B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19915930 1999-04-09

Publications (1)

Publication Number Publication Date
ZA200107978B true ZA200107978B (en) 2003-03-26

Family

ID=7903946

Family Applications (2)

Application Number Title Priority Date Filing Date
ZA200107890A ZA200107890B (en) 1999-04-09 2001-09-26 Prodrugs of thrombin inhibitors.
ZA200107978A ZA200107978B (en) 1999-04-09 2001-09-28 Low-molecular inhibitors of complement proteases.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ZA200107890A ZA200107890B (en) 1999-04-09 2001-09-26 Prodrugs of thrombin inhibitors.

Country Status (22)

Country Link
US (1) US6683055B1 (xx)
EP (1) EP1169338B1 (xx)
JP (1) JP4489976B2 (xx)
KR (1) KR20010108477A (xx)
CN (1) CN1351609A (xx)
AT (1) ATE281466T1 (xx)
AU (1) AU4111700A (xx)
BG (1) BG105978A (xx)
BR (1) BR0009678A (xx)
CA (1) CA2369378A1 (xx)
CZ (1) CZ20013577A3 (xx)
DE (1) DE50008510D1 (xx)
HK (1) HK1045846A1 (xx)
HU (1) HUP0203167A3 (xx)
IL (1) IL145771A0 (xx)
MX (1) MXPA01010114A (xx)
NO (1) NO20014876L (xx)
PL (1) PL351441A1 (xx)
SK (1) SK14232001A3 (xx)
TR (1) TR200102913T2 (xx)
WO (1) WO2000061608A2 (xx)
ZA (2) ZA200107890B (xx)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL145772A0 (en) * 1999-04-09 2002-07-25 Basf Ag Prodrugs of thrombin inhibitors
ATE517910T1 (de) * 2000-08-11 2011-08-15 Wilex Ag NICHT-KOVALENTE INHIBITOREN VON UROKINASE UND BLUTGEFÄßBILDUNG
NZ547626A (en) * 2000-08-11 2007-10-26 Wilex Ag Non-covalent inhibitors of urokinase and blood vessel formation
WO2003070229A2 (de) * 2002-02-22 2003-08-28 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Verwendung von proteinaseinhibitoren zur behandlung von autoimmunerkrankungen
EP1483283A4 (en) 2002-03-13 2007-04-11 Signum Biosciences Inc MODULATION OF PROTEIN METHYLATION AND PHOSPHOPROTEIN PHOSPHATE
EP1499306A4 (en) 2002-04-12 2007-03-28 Merck & Co Inc BICYCLIC AMIDE
ES2387275T3 (es) * 2003-05-15 2012-09-19 Genentech, Inc. Métodos y composiciones para la prevención y el tratamiento de la sepsis
TW200519105A (en) * 2003-10-20 2005-06-16 Lg Life Science Ltd Novel inhibitors of DPP-IV, methods of preparing the same, and pharmaceutical compositions containing the same as an active agent
CN1304568C (zh) * 2004-07-05 2007-03-14 中国人民解放军第二军医大学 新型人补体C1r样丝氨酸蛋白酶类似物,其编码序列及用途
CA2601777A1 (en) * 2005-02-03 2006-08-10 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
US7923041B2 (en) 2005-02-03 2011-04-12 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
DE602006010834D1 (de) * 2005-03-16 2010-01-14 Janssen Pharmaceutica Nv Neue thiophensulfoximine zur behandlung von komplementvermittelten krankheiten und leiden
AU2009239430B2 (en) 2008-04-21 2015-01-22 Signum Biosciences, Inc. Compounds, compositions and methods for making the same
CN102464701B (zh) * 2010-11-08 2015-10-21 上海医药工业研究院 一类新型化合物、其制备方法及用途
PH12014500625B1 (en) 2011-10-14 2018-12-12 Bristol Myers Squibb Co Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
WO2013055984A1 (en) 2011-10-14 2013-04-18 Bristol-Myers Squibb Company Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
CN103987696B (zh) 2011-10-14 2016-12-21 百时美施贵宝公司 作为因子xia抑制剂的取代的四氢异喹啉化合物
TR201807316T4 (tr) 2012-10-12 2018-06-21 Bristol Myers Squibb Co Bir faktör XIa inhibitörünün kristalli formları.
EP2906541B1 (en) 2012-10-12 2017-11-22 Bristol-Myers Squibb Company Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
EP2906552B1 (en) 2012-10-12 2017-11-22 Bristol-Myers Squibb Company Guanidine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
ES2712699T3 (es) 2013-03-25 2019-05-14 Bristol Myers Squibb Co Tetrahidroisoquinolinas que contienen azoles sustituidos como inhibidores del factor XIa
SI3099687T1 (en) 2014-01-31 2018-08-31 Bristol-Myers Squibb Company Macrocycles with hetrocyclic p2' groups as factor xia inhibitors
NO2760821T3 (xx) 2014-01-31 2018-03-10
EP3189047B1 (en) 2014-09-04 2018-12-26 Bristol-Myers Squibb Company Diamide macrocycles that are fxia inhibitors
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
EP3941462A4 (en) * 2019-03-22 2023-04-05 Achillion Pharmaceuticals, Inc. PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT-MEDIED DISEASES
US20250171423A1 (en) * 2020-09-23 2025-05-29 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement mediated disorders

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3738910A1 (de) 1987-11-17 1989-05-24 Basf Ag Tributylammoniumsalz von 1,1-dicyano-2-hydroxy-3-chlorprop-1-en, ein verfahren zu seiner herstellung sowie ein verfahren zur herstellung von 2-amino-4-chlor-3-cyano-5-formylthiophen
AU675981B2 (en) * 1992-12-02 1997-02-27 Bristol-Myers Squibb Company Guanidinyl-substituted heterocyclic thrombin inhibitors
SE9301916D0 (sv) * 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
DE4421052A1 (de) * 1994-06-17 1995-12-21 Basf Ag Neue Thrombininhibitoren, ihre Herstellung und Verwendung
DE4443390A1 (de) 1994-12-06 1996-06-13 Basf Ag Neue dipeptidische p-Amidinobenzylamide mit N-terminalen Sulfonyl- bzw. Aminosulfonylresten
FI973282L (fi) * 1995-02-10 1997-08-08 Basf Ag Trombiinin inhibiittoreita
CZ245797A3 (cs) * 1995-02-17 1998-06-17 Basf Aktiengesellschaft Derivát amidinu dipeptidu jako inhibitor thrombinu
AR005245A1 (es) * 1995-12-21 1999-04-28 Astrazeneca Ab Prodrogas de inhibidores de trombina, una formulación farmaceutica que las comprende, el uso de dichas prodrogas para la manufactura de un medicamento y un procedimiento para su preparacion
DE19632773A1 (de) 1996-08-14 1998-02-19 Basf Ag Neue Thrombininhibitoren
DE19632772A1 (de) * 1996-08-14 1998-02-19 Basf Ag Neue Benzamidine
DE19635674A1 (de) 1996-09-03 1998-03-05 Basf Ag Verfahren zur Herstellung von Amidinen
US6653340B1 (en) * 1997-06-03 2003-11-25 Biocryst Pharmaceuticals, Inc. Compounds useful in the complement, coagulat and kallikrein pathways and method for their preparation
AU2424499A (en) * 1998-01-26 1999-08-09 Basf Aktiengesellschaft Heterocyclic amidines as callicrein protease inhibitors
EP1051431A1 (de) * 1998-01-26 2000-11-15 Basf Aktiengesellschaft Thrombininhibitoren

Also Published As

Publication number Publication date
US6683055B1 (en) 2004-01-27
EP1169338B1 (de) 2004-11-03
HUP0203167A2 (hu) 2003-02-28
TR200102913T2 (tr) 2002-01-21
CZ20013577A3 (cs) 2002-07-17
ATE281466T1 (de) 2004-11-15
MXPA01010114A (es) 2002-07-30
ZA200107890B (en) 2003-11-26
SK14232001A3 (sk) 2002-06-04
IL145771A0 (en) 2002-07-25
CN1351609A (zh) 2002-05-29
DE50008510D1 (de) 2004-12-09
AU4111700A (en) 2000-11-14
BG105978A (bg) 2002-07-31
WO2000061608A2 (de) 2000-10-19
BR0009678A (pt) 2002-01-22
EP1169338A2 (de) 2002-01-09
CA2369378A1 (en) 2000-10-19
NO20014876L (no) 2001-12-04
JP2002542164A (ja) 2002-12-10
PL351441A1 (en) 2003-04-22
KR20010108477A (ko) 2001-12-07
JP4489976B2 (ja) 2010-06-23
WO2000061608A3 (de) 2001-01-11
NO20014876D0 (no) 2001-10-08
HK1045846A1 (zh) 2002-12-13
HUP0203167A3 (en) 2003-09-29

Similar Documents

Publication Publication Date Title
ZA200107978B (en) Low-molecular inhibitors of complement proteases.
DE69725878D1 (de) Zusammensetzungen zur polynukleotidabgabe
HUP0200347A3 (en) N-cyanomethylamides as protease inhibitors, pharmaceutical compositions containing them and their use
HUP0100100A3 (en) Hepatitis c inhibitor peptide analogues, pharmaceutical compositions comprising thereof and their use
HUP0500456A3 (en) Hepatitis c tripeptide inhibitors, pharmaceutical compositions comprising thereof and their use
IL134042A0 (en) Modified dorsal tissue affecting factor and compositions
PL340560A1 (en) Heteroaryl aminoguanidines and alkoxyguanidines and their application as protease inhibitors
WO1996040055A3 (en) Biological agent compositions
AU5751600A (en) Eliminating gas blocking in electrokinetic pumping systems
ZA992549B (en) Incorporation of active substances in carrier matrixes.
NO995891L (no) LH-RH peptidanaloger, anvendelser og farmasoeytiske blandinger inneholdende disse
GB9717905D0 (en) Lipid-containing compositions and uses thereof
AU8738401A (en) Novel kallikrein gene
HUP9900390A3 (en) Serine protease inhibitors, and pharmaceutical compositions containing them
EP0643074A3 (en) Inhibitors of viral infection and proliferation.
ZA962133B (en) Cyclic urea HIV protease inhibitors.
ID20839A (id) Bahan acuan pestisida berlapis lebih baik, pengolahan pada pembuatannya serta komposisi-komposisi yang terkandung di dalamnya
AU2001244286A1 (en) Peptide sequences comprising one or several protein binding units of the ena/vasp family, and uses thereof
NZ525774A (en) Use of SARP-1 for the treatment and/or prevention of scleroderma
ZA946325B (en) Retroviral protease inhibitors and combinations thereof.
EP1073449A4 (en) AMINO ACID AMIDINOHYDRAZONES, ALCOXYGUANIDINES AND AMINOGUANIDINES FOR USE AS ENZYME PROTEASE INHIBITORS
ZA9710254B (en) LH-RH peptide analogues, their uses and pharmaceutical composition containing them.
IT1290910B1 (it) 2-amminotetralina otticamente attiva, procedimento per la sua preparazione e composizioni farmaceutiche che la contengono, attive
AU1998201A (en) Modular transport systems for molecular substances and production and use thereof
WO1998018818A3 (en) Hepatitis b inhibitors